Charles River Laboratories International (CRL) Asset Writedowns and Impairment (2022 - 2026)

Charles River Laboratories International has reported Asset Writedowns and Impairment for 5 years, with the latest figure at $10.4 million in Q2 2026.

• On a quarterly basis, Asset Writedowns and Impairment fell 49.5% year-over-year to $10.4 million in Q2 2026; TTM through Jun 2026 was $254.2 million, a 314.66% increase from a year earlier, with the FY2025 full-year figure at $259.1 million, up 399.91% from the prior year.
• Asset Writedowns and Impairment was $10.4 million for Q2 2026 at Charles River Laboratories International, down from $15.9 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $222.9 million in Q4 2025, with the low at -$7000.0 in Q3 2023.
• Average Asset Writedowns and Impairment over 5 years is $25.2 million, with a median of $10.5 million recorded in 2023.
• The largest YoY upside for Asset Writedowns and Impairment was 126071.43% in 2024 against a maximum downside of 80.39% in 2024.
• Over 5 years, Asset Writedowns and Impairment stood at $6.7 million in 2022, then surged by 134.25% to $15.7 million in 2023, then jumped by 71.88% to $27.0 million in 2024, then jumped by 725.54% to $222.9 million in 2025, then tumbled by 95.33% to $10.4 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $10.4 million (Q2 2026), $15.9 million (Q1 2026), and $222.9 million (Q4 2025), per Business Quant data.